Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
NCT00572455
Last updated date
ABOUT THIS STUDY
To evaluate the safety and efficacy of PF-04217329.
Study Location
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
By phone
Pfizer Clinical Trials Contact Center
1-800-718-1021
Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Primary Open Angle Glaucoma, Ocular Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details
- Diagnosis of primary open-angle glaucoma (including pigmentary or pseudoexfoliative) or ocular hypertension in 1 or both eyes.
- Qualifying intraocular pressure (IOP) in the same eye at the Eligibility 1 and 2 measurements.
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details
- Closed/barely open anterior chamber angle or a history of acute angle closure in
either eye.
- Anticipate the need to initiate or modify medication (systemic or topical) that is
known to affect intraocular pressure (IOP) during the study period.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
Clinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
Primary Open Angle Glaucoma, Ocular HypertensionA Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension
NCT01379144
- Sydney, New South Wales
- Sydney, New South Wales
- Adelaide, South Australia
- Brno,
- Prague 5,
- Prague 9,
- Praha 2,
- Praha 2,
- Marseille,
- Marseille,
- Paris,
- Strasbourg,
- Thessaloniki,
- Lahore, Punjab
- Lahore, Punjab
- Karachi, Sindh
- Karachi, Sindh
- Coimbra,
- Lisboa,
- Matosinhos,
- Bangkok,
- Bangkok,
- Birmingham,
- Glasgow,
- Sunderland,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Primary Open Angle Glaucoma, Ocular HypertensionSafety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.
NCT00572455
- Artesia, California
- Newport Beach, California
- Petaluma, California
- Poway, California
- Daytona Beach, Florida
- Fort Myers, Florida
- Ormond Beach, Florida
- Atlanta, Georgia
- Atlanta, Georgia
- Morrow, Georgia
- Evansville, Indiana
- Louisville, Kentucky
- Rochester, New York
- Charlotte, North Carolina
- High Point, North Carolina
- Tulsa, Oklahoma
- Bristol, Pennsylvania
- Philadelphia, Pennsylvania
- Charleston, South Carolina
- Memphis, Tennessee
- Austin, Texas
- Austin, Texas
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure. | |||
| Official Title ICMJE | A 2-Stage, Phase 2, Double-Masked, Randomized, Vehicle Controlled, Dose Response Trial Of PF-04217329 And The Marketed Formulation Of Latanoprost In Patients With Primary Open Angle Glaucoma Or Ocular Hypertension. | |||
| Brief Summary | To evaluate the safety and efficacy of PF-04217329. | |||
| Detailed Description | Not Provided | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 2 | |||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment | |||
| Condition ICMJE |
| |||
| Intervention ICMJE |
| |||
| Study Arms ICMJE |
| |||
| Publications * | Schachar RA, Raber S, Courtney R, Zhang M. A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr Eye Res. 2011 Sep;36(9):809-17. doi: 10.3109/02713683.2011.593725. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 317 | |||
| Original Enrollment ICMJE | 256 | |||
| Actual Study Completion Date ICMJE | June 2009 | |||
| Actual Primary Completion Date | June 2009 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT00572455 | |||
| Other Study ID Numbers ICMJE | A0191001 | |||
| Has Data Monitoring Committee | Yes | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Director, Clinical Trial Disclosure Group, Pfizer Inc | |||
| Study Sponsor ICMJE | Pfizer | |||
| Collaborators ICMJE | Not Provided | |||
| Investigators ICMJE |
| |||
| PRS Account | Pfizer | |||
| Verification Date | February 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||